A detailed history of Northern Trust Corp transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 68,474 shares of AADI stock, worth $162,968. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,474
Previous 158,680 56.85%
Holding current value
$162,968
Previous $231,000 38.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.32 - $2.06 $119,071 - $185,824
-90,206 Reduced 56.85%
68,474 $141,000
Q2 2024

Aug 14, 2024

SELL
$1.46 - $2.31 $181 - $286
-124 Reduced 0.08%
158,680 $231,000
Q1 2024

May 14, 2024

SELL
$1.59 - $2.44 $5,658 - $8,683
-3,559 Reduced 2.19%
158,804 $371,000
Q4 2023

Feb 13, 2024

BUY
$1.97 - $5.41 $41,793 - $114,773
21,215 Added 15.03%
162,363 $327,000
Q3 2023

Nov 13, 2023

BUY
$4.84 - $7.13 $62,073 - $91,442
12,825 Added 9.99%
141,148 $683,000
Q2 2023

Aug 11, 2023

BUY
$6.84 - $8.56 $54,665 - $68,411
7,992 Added 6.64%
128,323 $877,000
Q1 2023

May 15, 2023

SELL
$6.85 - $13.0 $14,891 - $28,262
-2,174 Reduced 1.77%
120,331 $871,000
Q4 2022

Feb 13, 2023

SELL
$11.99 - $14.5 $46,293 - $55,984
-3,861 Reduced 3.06%
122,505 $1.57 Million
Q3 2022

Nov 14, 2022

SELL
$12.03 - $14.22 $94,531 - $111,740
-7,858 Reduced 5.85%
126,366 $1.79 Million
Q2 2022

Aug 12, 2022

BUY
$11.57 - $17.92 $1.13 Million - $1.76 Million
97,966 Added 270.19%
134,224 $1.65 Million
Q1 2022

May 13, 2022

SELL
$16.65 - $24.97 $9,157 - $13,733
-550 Reduced 1.49%
36,258 $615,000
Q4 2021

Feb 08, 2022

BUY
$19.32 - $29.02 $711,130 - $1.07 Million
36,808 New
36,808 $889,000

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $50M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.